More obviously, in a prostate cancer murine model, a combination cocktail containing anti-CTLA-4 antibody (i.p., 100 μg/mouse), anti-PD-1 antibody (i.p., 250 μg/mouse), anti-4-1BB antibody (i.p., 200 μg/mouse) with the STING agonist CDG (i.t., 25 μg/mouse) caused unprecedented tumor regression in 75% of the mice, demonstrating a higher cure rate than ICI monotherapy [153]. The gene discussed is CTLA4; the disease is neoplasm.